Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
Date:11/1/2007

xcluded from

non-GAAP net income. Year-to-date, the Company reduced GAAP net loss

to $26.2 million from $52.2 million for the same period of 2006.

-- As of September 30, 2007, the Company had $876.3 million in cash,

cash equivalents and marketable securities. The outstanding

principal amount of convertible debt was $250.0 million.

Full-Year 2007 Financial Guidance

The Company is raising its full-year 2007 financial guidance for the second time, having also raised its guidance in July 2007. Full-year 2007 financial guidance as of January 4, July 26, and November 1 of this year, is as follows:

2007 Financial Guidance as of as of as of

(dollars in millions) Jan 4, 2007 Jul 26, 2007 Nov 1, 2007

VELCADE U.S. net sales $240 - 260 $250 - 260 $~265

Royalties $140 - 150 $150 - 155 $~160

Non-GAAP R&D, SG&A

expense $~425 $440 - 450 $440 - 450

GAAP R&D, SG&A expense $455 - 465 $465 - 480 $465 - 475

Non-GAAP net income $10 - 20 $20 - 30 $40 - 45

GAAP net loss (3) $60 - 90 $50 - 60 $30 - 35

Amortization $~34 $~34 $~34

Stock-based compensation $30 - 40 $25 - 30 $~25

Restructuring $15 - 25 $15 - 20 $~15

Cash, cash equivalents,

and marketable

securities $ > 800 $ > 800 $ > 800

VELCADE Highlights

"VELCADE sales showed considerable strength this quarter resulting from the convergence of a number of growth drivers. In multiple myeloma, VELCADE use increased significantly with expanded use of VELCADE based combinations and re-treatment. In mantle cell lymphoma, our launch continues successfully with more
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... OAKLAND, Calif., September 22, 2014 Patients who were treated ... a hemorrhagic stroke were significantly more likely to survive ... published today in JAMA Neurology . This study ... that the use of cholesterol-lowering statins can improve survival ... by a constriction or obstruction of a blood vessel ...
(Date:9/22/2014)... 22, 2014 Research and ... of the "Global Biotechnology Reagents Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are chemical ... system to detect and examine another substance to ... in laboratories to prepare, collect, and examine specimens ...
(Date:9/22/2014)... of circulating tumor cells (CTCs) in a mouse model ... in several groups of CTCs, including significant differences from ... to generate metastases. In their study reported in ... investigators from the Massachusetts General Hospital (MGH) Cancer Center ... unexpected factors that may prove to be targets for ...
(Date:9/22/2014)... way to create a highly sensitive chemical sensor based ... have unique electronic properties that the researchers were able ... by 300 times. , The study is available online ... , Amin Salehi- Khojin, asst professor of mechanical and ... student and Bijandra Kumar, post doc where they are ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... KENILWORTH and WHITEHOUSE STATION, N.J., April 25 ,Schering-Plough/MERCK ... letter from the U.S. Food and Drug Administration,(FDA) ... montelukast for,the treatment of allergic rhinitis symptoms in ... New Drug Application filing for loratadine/montelukast was accepted,by ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that it ... that the Company is not in,compliance with the $1.00 ... Global Market pursuant to Marketplace Rule 4450,(a)(5). This notification, ... is a standard communication when the bid price of ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that it ... Conference being held April 30 - May 2, ... Zwanziger, Chief Executive Officer, will,attend. His presentation is ...
Cached Biology Technology:Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 2Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 3Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
(Date:9/23/2014)... of scientists has identified a gene mutation that ... which the bone marrow fails to produce normal ... which three generations had blood disorders, the researchers ... telomeres, chromosomal structures with crucial roles in normal ... help suggest future molecular-based treatments that bypass the ...
(Date:9/23/2014)... the development of animals and plants. The central problem ... translated in a reliable manner to give specific spatial ... of stripe formation is a classic paradigm in developmental ... the French flag, is caused by a gradient of ... low concentrations of the morphogen a "blue", "white" or ...
Breaking Biology News(10 mins):Gene mutation discovered in blood disorder 2Recreating the stripe patterns found in animals by engineering synthetic gene networks 2
... the cacao genome is complete, a consortium of academic, ... scientists performed much of the sequencing work, which is ... website of the Cacao Genome Database project. Despite ... Inc., Cacao Genome Database scientists say one of their ...
... , BOSTON (9-15-10) -- A team led by Boston ... four-year grant from the National Institutes of Health to ... could lead to individual genome sequencing for less than ... on an initial, $2.2 million NIH grant and led ...
... 15 September 2010 -- The European Society for Medical Oncology ... the advancement of medical research. The awards will be presented ... 35th ESMO Congress, to take place from 8-12 October in ... the 2010 ESMO Award for his key role in the ...
Cached Biology News:Chocolate farmers could benefit from newly sequenced cacao genome 2Chocolate farmers could benefit from newly sequenced cacao genome 3Chocolate farmers could benefit from newly sequenced cacao genome 4BU team wins $4.1M genome grant 2Top cancer specialists receive ESMO awards 2Top cancer specialists receive ESMO awards 3Top cancer specialists receive ESMO awards 4
... synthetic peptide whose sequence is from the C-terminal end of the mouse ... from amino acids 429 to 448 of RAR*. The sequence of ... V - S - P - S - S - V - ... Q - S - P - L - L - Q ...
... The ELx50 is a fast and ... equipped with our patented Dual-ActionTM 16-channel manifold. ... of the dispense and aspiration manifolds for ... 96- and 384-well formats. The problem of ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Biology Products: